Al­ny­lam gets an ad­comm for On­pat­tro treat­ment in AT­TR amy­loi­do­sis

Al­ny­lam Phar­ma­ceu­ti­cals is hop­ing its lat­est round of da­ta for On­pat­tro’s treat­ment of AT­TR is enough to sat­is­fy the FDA. But they’ll have to make it through their ad­vi­sors first.

Al­ny­lam an­nounced Tues­day that the FDA has ac­cept­ed a sup­ple­men­tal NDA for On­pat­tro, oth­er­wise known as patisir­an, to treat the car­diomy­opa­thy of transthyretin-me­di­at­ed (AT­TR) amy­loi­do­sis, and will be hold­ing an ad­vi­so­ry com­mit­tee to dis­cuss the ap­pli­ca­tion. How­ev­er, the date of the ad­comm was not im­me­di­ate­ly dis­closed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER